Free Trial
NASDAQ:NKTX

Nkarta Q4 2024 Earnings Report

Nkarta logo
$1.76 -0.06 (-3.04%)
As of 11:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nkarta EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.41
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Nkarta Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nkarta Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 26, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Nkarta's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Monday, August 11, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Nkarta Earnings Headlines

Leerink Partnrs Has Pessimistic View of Nkarta Q2 Earnings
Trump Knows Exactly What He's Doing
REVEALED: $194 Trillion Trump Market Pattern Trump fires off a tweet and stocks tank… He gives a speech and the markets soar… Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets. And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance.
See More Nkarta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nkarta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nkarta and other key companies, straight to your email.

About Nkarta

Nkarta (NASDAQ:NKTX), a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

View Nkarta Profile

More Earnings Resources from MarketBeat